J. Sasaki

发表

Prognostic significance of daily physical activity after first acute myocardial infarction.

K. Kitajima, J. Sasaki, S. Kono, 1990, American heart journal.

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance

J. Sasaki, S. Kono, Y. Ikeda, 2008, Clinical therapeutics.

Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyceridemia — Randomized double-blind, cross-over placebo controlled study

J. Sasaki, K. Arakawa, Y. Ikeda, 2000 .

A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.

J. Sasaki, N. Yamada, H. Mabuchi, 2002, Atherosclerosis.

Clinical Efficacy of Pitavastatin, a New 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, in Patients with Hyperlipidemia

J. Sasaki, N. Yamada, H. Mabuchi, 2002, Arzneimittelforschung.

Sitagliptin Improves Plasma Apolipoprotein Profile in Type 2 Diabetes: A Randomized Clinical Trial of Sitagliptin Effect on Lipid and Glucose Metabolism (SLIM) Study.

J. Sasaki, S. Kono, H. Sugihara, 2020, Diabetes research and clinical practice.

Japanese dietary lifestyle and cardiovascular disease.

Hiroaki Tanaka, J. Sasaki, S. Koba, 2011, Journal of atherosclerosis and thrombosis.

Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia.

J. Sasaki, A. Matsunaga, N. Sakuma, 2014, Journal of atherosclerosis and thrombosis.

Marked elevation in serum apolipoprotein E in a case of heterozygous cholesteryl ester transfer protein deficiency.

J. Sasaki, J. Kobayashi, N. Morisaki, 2000, Clinica chimica acta; international journal of clinical chemistry.

Association of a Novel 3-Amino Acid Deletion Mutation of Apolipoprotein E (Apo E Tokyo) with Lipoprotein Glomerulopathy

T. Saruta, J. Sasaki, S. Oikawa, 1999, Nephron.

A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.

T. Kita, J. Sasaki, K. Arakawa, 1999, Kidney international.

A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy.

J. Sasaki, K. Uchida, S. Oikawa, 1999, Kidney international.

Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

J. Sasaki, H. Jingami, S. Oikawa, 1997, Journal of the American Society of Nephrology : JASN.

Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-224 --> Gln) in a hyperlipidemic patient with xanthomatosis.

Y. Ito, J. Sasaki, K. Arakawa, 1996, Biochimica et biophysica acta.

Population frequency of apolipoprotein E5 (Glu3→Lys) and E7 (Glu244→Lys, Glu245→Lys) variants in western Japana

J. Sasaki, K. Arakawa, A. Matsunaga, 1995, Clinical genetics.

Apolipoprotein E1 Lys-146----Glu with type III hyperlipoproteinemia.

J. Sasaki, K. Arakawa, A. Matsunaga, 1992, Biochimica et biophysica acta.

Treatment - therapeutic lifestyle modification.

T. Funahashi, K. Shimamoto, H. Daida, 2008, Journal of atherosclerosis and thrombosis.

Other high-risk conditions.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Strategy for treating elderly Japanese with hypercholesterolemia *

Y. Matsuzawa, T. Kita, J. Sasaki, 2004 .

The effects of long-term low intensity aerobic training and detraining on serum lipid and lipoprotein concentrations in elderly men and women

Hiroaki Tanaka, J. Sasaki, K. Arakawa, 2004, European Journal of Applied Physiology and Occupational Physiology.

The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid.

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2012, Journal of atherosclerosis and thrombosis.

In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques.

J. Sasaki, K. Arakawa, S. Horiuchi, 2000, Atherosclerosis.

A Comparative Study of Olmesartan and Valsartan on Insulin Sensitivity in Hypertensive Patients with Diabetes Mellitus or Impaired Glucose Tolerance (OVIS Study)

J. Sasaki, S. Kono, S. Biro, 2014 .

Cerebrovascular diseases.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin - effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study).

J. Sasaki, S. Kono, S. Biro, 2012, Journal of atherosclerosis and thrombosis.

Committee Report 3 Goals of Dyslipidemia Management

T. Funahashi, K. Shimamoto, H. Daida, 2007 .

Goals of dyslipidemia management.

T. Funahashi, K. Shimamoto, H. Daida, 2007, Journal of atherosclerosis and thrombosis.

Relationship Between Coronary Events and Serum Cholesterol During 10 Years of Low-Dose Simvastatin Therapy

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2008 .

Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2003, Circulation journal : official journal of the Japanese Circulation Society.

Effect of mild aerobic exercise on serum lipids and apolipoproteins in patients with coronary artery disease.

Hiroaki Tanaka, J. Sasaki, K. Arakawa, 1987, Japanese heart journal.

Primary Cardiovascular Events and Serum Lipid Levels in Elderly Japanese with Hypercholesterolemia Undergoing 6‐Year Simvastatin Treatment: A Subanalysis of the Japan Lipid Intervention Trial

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2004, Journal of the American Geriatrics Society.

Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT).

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2002, Circulation journal : official journal of the Japanese Circulation Society.

Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: the Japan lipid intervention trial (J-LIT)

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2000 .

Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study.

J. Sasaki, Kyosuke Yamamoto, M. Ageta, 2002, Clinical therapeutics.

Low serum apolipoprotein A-I level in patients with vasospastic angina.

J. Sasaki, K. Arakawa, T. Kawano, 1993, American heart journal.

Committee Report 16 Women

S. Kihara, S. Yamashita, T. Hiro, 2014 .

Women. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Elderly patients.

T. Funahashi, K. Shimamoto, H. Daida, 2008, Journal of atherosclerosis and thrombosis.

American women ( aged 30 − 55 years at Women

T. Funahashi, K. Shimamoto, H. Daida, 2008 .

Risk Factors of Atherosclerotic Diseases

T. Funahashi, K. Shimamoto, H. Daida, 2007 .

Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease.

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2010, Circulation journal : official journal of the Japanese Circulation Society.

Isolation and characterization of human apolipoprotein A-I Fukuoka (110 Glu----Lys). A novel apolipoprotein variant.

J. Sasaki, K. Arakawa, Y. Ikehara, 1990, Biochimica et biophysica acta.

Effect of Nifedipine on Serum Lipoprotein Metabolism in Patients with Essential Hypertension

J. Sasaki, K. Arakawa, 1989 .

Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines.

J. Sasaki, K. Arakawa, T. Sata, 1984, Atherosclerosis.

Seasonal variation of serum high density lipoprotein cholesterol levels in men.

J. Sasaki, K. Arakawa, M. Ikeda, 1983, Atherosclerosis.

Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects.

J. Sasaki, N. Yamada, H. Mabuchi, 2003, Metabolism: clinical and experimental.

Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000.

Y. Ouchi, Y. Matsuzawa, T. Kita, 2005, Journal of atherosclerosis and thrombosis.

Other types of primary hyperlipoproteinemia(hyperlipidemia). Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese.

T. Funahashi, K. Shimamoto, H. Daida, 2007, Journal of atherosclerosis and thrombosis.

Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2012, Journal of atherosclerosis and thrombosis.

Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day−1

J. Sasaki, S. Kono, T. Saikawa, 2010, Hypertension Research.

Relation of serum total cholesterol and other risk factors to risk of coronary events in middle-aged and elderly Japanese men with hypercholesterolemia: the Kyushu Lipid Intervention Study.

J. Sasaki, S. Kono, K. Arakawa, 2004, Circulation journal : official journal of the Japanese Circulation Society.

Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.

J. Sasaki, S. Kono, K. Arakawa, 2003, Circulation journal : official journal of the Japanese Circulation Society.

Treatment--drug therapy.

T. Funahashi, K. Shimamoto, H. Daida, 2008, Journal of atherosclerosis and thrombosis.

A trilogy of primary prevention statin trials. Panel discussion.

A. Gotto, Y. Matsuzawa, F. Sacks, 2007, Atherosclerosis. Supplements.

Serum lipid survey and its recent trend in the general Japanese population in 2000.

Y. Ouchi, Y. Matsuzawa, T. Kita, 2005, Journal of atherosclerosis and thrombosis.

Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.

Y. Matsuzawa, J. Sasaki, K. Arakawa, 2002, Journal of atherosclerosis and thrombosis.

A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.

J. Sasaki, S. Kono, K. Arakawa, 1998, Clinical therapeutics.

Antioxidative Effects of Fluvastatin on Superoxide Anion Activated by Angiotensin II in Human Aortic Smooth Muscle Cells

J. Sasaki, K. Arakawa, A. Matsunaga, 2002, Cardiovascular Drugs and Therapy.

A cysteine-containing truncated apo A-I variant associated with HDL deficiency.

J. Sasaki, K. Arakawa, J. Albers, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Committee Report 14 Cerebrovascular Diseases

S. Kihara, S. Yamashita, T. Hiro, 2014 .

Compound heterozygosity for an apolipoprotein A1 gene promoter mutation and a structural nonsense mutation with apolipoprotein A1 deficiency.

Wei Huang, J. Sasaki, K. Arakawa, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Apolipoprotein E epsilon 4.

S. Sakoda, J. Sasaki, M. Osame, 1994, Neurology.

Diagnosis of Atherosclerosis

S. Kihara, S. Yamashita, T. Hiro, 2014 .

Diagnosis of atherosclerosis. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Detection of a point mutation in cholesteryl ester transfer protein gene by polymerase chain reaction-mediated site-directed mutagenesis.

J. Sasaki, K. Arakawa, A. Matsunaga, 1993, Biochimica et biophysica acta.

Determination by the SRID Method of Normal Values of Serum Apolipoproteins (A-I, A-II, B, C-II, C-III, and E) in Normolipidemic Healthy Japanese Subjects

Y. Matsuzawa, J. Sasaki, Y. Akanuma, 1986 .

Coronary artery disease. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Polymorphisms of apolipoprotein e and methylenetetrahydrofolate reductase in the Japanese population.

Y. Ouchi, Y. Matsuzawa, T. Kita, 2007, Journal of atherosclerosis and thrombosis.

An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population

J. Sasaki, J. Breslow, A. Matsunaga, 1995, Human Genetics.

Prevalence of the metabolic syndrome in elderly and middle-aged Japanese

Y. Ouchi, Y. Matsuzawa, T. Kita, 2010 .

Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with hypercholesterolemia: The Kyushu Lipid Intervention Study (KLIS)

J. Sasaki, K. Arakawa, 2000 .

Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.

J. Sasaki, K. Arakawa, A. Matsunaga, 1992, Atherosclerosis.

The association among fat distribution, physical fitness, and the risk factors of cardiovascular disease in obese women.

J. Sasaki, H. Tanaka, T. Taniguchi, 1995, Obesity research.

Marked decrease in plasma apolipoprotein A-I and high density lipoprotein-cholesterol in a case with Werner syndrome.

J. Sasaki, K. Yokote, J. Kobayashi, 2000, Clinica chimica acta; international journal of clinical chemistry.

Physical Fitness and Body Fat Distribution: Relation to Risk Factors for Metabolic Diseases in Obese Women

Hiroaki Tanaka, J. Sasaki, K. Arakawa, 1999 .

Alcohol consumption, serum lipids and severity of angiographically determined coronary artery disease.

J. Sasaki, S. Kono, K. Arakawa, 1990, The American journal of cardiology.

Relationships between plasma fatty acid composition and coronary artery disease.

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2011, Journal of atherosclerosis and thrombosis.

Metabolic syndrome.

T. Funahashi, K. Shimamoto, H. Daida, 2008, Journal of atherosclerosis and thrombosis.

Body mass index as an independent indicator of blood pressure in normotensive Japanese.

J. Sasaki, S. Kono, K. Arakawa, 1990, Diabetes research and clinical practice.

EFFECTS OF 9 MONTHS MILD AEROBIC TRAINING ON SERUM LIPIDS AND LIPOPROTEIN CONCENTRATIONS IN OLDER THAN 65 YEARS MEN AND WOMEN WITH HYPERTENSION

Hiroaki Tanaka, J. Sasaki, A. Kiyonaga, 1992 .

Effect of mild aerobic exercise on lipid and apolipoprotein levels in patients with essential hypertension.

J. Sasaki, K. Arakawa, H. Urata, 1988, Japanese heart journal.

Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis.

J. Sasaki, S. Kono, K. Arakawa, 1989, Atherosclerosis.

Effect of Ketanserin on Lipoproteins in Patients with Essential Hypertension

J. Sasaki, K. Arakawa, K. Saku, 2012, Drugs.

Mild Exercise Therapy Increases Serum High Density Lipoprotein2 Cholesterol Levels in Patients with Essential Hypertension

J. Sasaki, K. Arakawa, H. Urata, 1989, The American journal of the medical sciences.

Effects of Monatepil, a Novel Calcium Antagonist with α1-Adrenergic Blocking Activity, on the Low-Density Lipoprotein Receptor in Human Skin Fibroblasts

J. Sasaki, K. Arakawa, A. Matsunaga, 1997, Cardiovascular Drugs and Therapy.

Effect of simvastatin on receptor mediated metabolism of low density lipoprotein in guinea pigs.

J. Sasaki, K. Arakawa, A. Matsunaga, 1991, Atherosclerosis.

Glycosylation of human LDL and its metabolism in human skin fibroblasts.

J. Sasaki, G. Cottam, 1982, Biochemical and biophysical research communications.

Glycosylation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo.

J. Sasaki, G. Cottam, 1982, Biochimica et biophysica acta.

Serum glycoproteins and severity of coronary atherosclerosis.

J. Sasaki, S. Kono, K. Arakawa, 1995, American heart journal.

A novel mutant, ApoA-I nichinan (Glu235-->0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells.

J. Sasaki, K. Arakawa, S. Horiuchi, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Erratum to “Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)” [Atherosclerosis 200 (2008) 135–140]

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2009 .

Family studies of the LDL receptor gene of relatively severe hereditary hypercholesterolemia associated with Achilles tendon xanthomas

K. Yamakawa, J. Sasaki, K. Arakawa, 1991, Human Genetics.

Nonenzymatic galactosylation of human LDL decreases its metabolism by human skin fibroblasts.

J. Sasaki, G. Cottam, V. Arora, 1982, Biochemical and biophysical research communications.

Nephrotic syndrome associated with hyper-high-density lipoproteinemia potentiated by prednisolone therapy.

J. Sasaki, K. Arakawa, S. Naito, 1985, Nephron.

Familial hypercholesterolemia.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Virus-mediated Transduction of Apolipoprotein E (ApoE)-Sendai Develops Lipoprotein Glomerulopathy in ApoE-deficient Mice*

Takashi Suzuki, H. Sasano, J. Sasaki, 2000, The Journal of Biological Chemistry.

Different coagulability and fibrinolytic activity during exercise depending on exercise intensities.

J. Sasaki, K. Arakawa, A. Kiyonaga, 1992, Thrombosis research.

Measurement of receptor-independent metabolism of low-density lipoprotein. An application of glycosylated low-density lipoprotein.

J. Sasaki, G. Cottam, T. Okamura, 1983, European journal of biochemistry.

Effects of arotinolol on exercise capacity and humoral factors during exercise in normal subjects

Hiroaki Tanaka, J. Sasaki, K. Arakawa, 1992, Cardiovascular Drugs and Therapy.

A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease.

J. Sasaki, S. Mochizuki, A. Endo, 2004, Atherosclerosis.

Effects of short- and long-term administration of nifedipine on serum lipoprotein metabolism in patients with mild hypertension

J. Sasaki, K. Arakawa, 1990, Cardiovascular Drugs and Therapy.

A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease

J. Sasaki, K. Arakawa, M. Umeno, 1992, Cardiovascular Drugs and Therapy.

Relationship of cigarette smoking to blood pressure and serum lipids.

J. Sasaki, S. Kono, K. Arakawa, 1990, Atherosclerosis.

Lipids and apolipoproteins in patients treated with major tranquilizers

J. Sasaki, K. Arakawa, M. Funakoshi, 1985, Clinical pharmacology and therapeutics.

Serum lipid and apolipoprotein profiles after onset of acute myocardial infarction.

J. Sasaki, T. Kawano, T. Sata, 1984, Japanese circulation journal.

Plasma and erythrocyte lipids in sickle cell anaemia.

M. Waterman, J. Sasaki, G. Cottam, 2008, Clinical and laboratory haematology.

Plasmin and thrombin inhibitors in essentially untreated patients with coronary artery spasm.

J. Sasaki, K. Arakawa, A. Matsunaga, 1993, International journal of cardiology.

Effects of captopril on opioid peptides during exercise and quality of life in normal subjects.

J. Sasaki, K. Arakawa, A. Kiyonaga, 1991, American heart journal.

Molecular Analysis of Apolipoprotein A-I and E Mutants in Japan

J. Sasaki, 2000 .

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2007, The Lancet.

Familial hypobetalipoproteinemia associated with hypothyroidism.

J. Sasaki, K. Arakawa, A. Matsunaga, 1995, Internal medicine.

Lack of association of rs3798220 with small apolipoprotein(a) isoforms and high lipoprotein(a) levels in East and Southeast Asians.

F. Kronenberg, A. Salem, J. Sasaki, 2015, Atherosclerosis.

Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects

Hiroaki Tanaka, J. Sasaki, K. Arakawa, 1992, Cardiovascular Drugs and Therapy.

Proline-rich protein is a glycoprotein and an acute phase reactant.

J. Sasaki, K. Arakawa, M. Funakoshi, 1988, Biochimica et biophysica acta.

Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.

T. Yanase, J. Sasaki, N. Yamada, 2007, Atherosclerosis.

Quantitation by 1H‐NMR of dolichol, cholesterol and choline‐containing lipids in extracts of normal and phathological thyroid tissue

J. Sasaki, Y. Yoshioka, J. Sasaki, 2000, NMR in biomedicine.

Recombinant proapoA-I(Lys107del) shows impaired lipid binding associated with reduced binding to plasma high density lipoprotein.

D. Sviridov, J. Sasaki, N. Fidge, 2001, Atherosclerosis.

Identification of two apolipoprotein variants, A‐I Karatsu (Tyr 100 → His) and A‐I Kurume (His 162 → Gin)

J. Sasaki, K. Arakawa, A. Matsunaga, 1996, Clinical genetics.

Identification of two apolipoprotein variants, A-I Kaho (Asp 51-->Val) and A-I Lys 107 deletion.

J. Sasaki, K. Arakawa, A. Matsunaga, 1996, Journal of atherosclerosis and thrombosis.

Primary hyperlipidemia.

T. Funahashi, K. Shimamoto, H. Daida, 2008, Journal of atherosclerosis and thrombosis.

Lipoprotein and Apolipoprotein Losses during Continuous Ambulatory Peritoneal Dialysis: ―腹膜透析排液中のリポ蛋白, アポ蛋白について―

J. Sasaki, K. Arakawa, K. Saku, 1987 .

Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults.

S. Yamashita, J. Sasaki, N. Yamada, 2002, Journal of atherosclerosis and thrombosis.

Long-term effect of CS-514 (HMG-CoA reductase inhibitor) on serum lipids, lipoproteins, and apolipoproteins in patinets with hypercholesterolemia

J. Sasaki, K. Arakawa, K. Saku, 1987 .

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2008, Atherosclerosis.

Evidence that C4b-binding protein (proline-rich protein) is synthesized by hepatocytes.

J. Sasaki, K. Arakawa, Y. Takada, 1991, Biochemical medicine and metabolic biology.

Lipoprotein Glomerulopathy: Renal Lipidosis Induced by Novel Apolipoprotein E Variants

J. Sasaki, S. Oikawa, Hiroshi Sato, 1999, Nephron.

Effects of gamma-oryzanol on serum lipids and apolipoproteins in dyslipidemic schizophrenics receiving major tranquilizers.

J. Sasaki, K. Arakawa, A. Matsunaga, 1990, Clinical therapeutics.

Gender difference in coronary events in relation to risk factors in Japanese hypercholesterolemic patients treated with low-dose simvastatin.

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2006, Circulation journal : official journal of the Japanese Circulation Society.

Right atrial vegetation in left ventricular‐right atrial communication

J. Sasaki, K. Arakawa, M. Fujino, 1987, Clinical cardiology.

Characterization of a new human A-I Yame by direct sequencing of chain react ion-am plif ied DNA apolipoprotein polymerase

J. Sasaki, K. Arakawa, Y. Teranishi, 1991 .

Research: Lipid Peroxidation Following Thermal Injury

C. Baxter, J. Sasaki, G. Cottam, 1983 .

Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia.

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2002, Circulation journal : official journal of the Japanese Circulation Society.

Diagnostic criteria for dyslipidemia.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese.

T. Funahashi, K. Shimamoto, H. Daida, 2007, Journal of atherosclerosis and thrombosis.

Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011).

T. Akasaka, M. Hayashi, R. Nohara, 2012, Circulation journal : official journal of the Japanese Circulation Society.

Treatment of hyperlipidemia from Japanese evidence.

J. Sasaki, S. Koba, 2006, Journal of atherosclerosis and thrombosis.

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2009, Atherosclerosis.

Relation of serum total cholesterol and other factors to risk of cerebral infarction in Japanese men with hypercholesterolemia.

J. Sasaki, S. Kono, K. Arakawa, 2004, Circulation journal : official journal of the Japanese Circulation Society.

Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients: Subanalysis of the JELIS Trial

Kortaro Tanaka, Y. Matsuzawa, K. Shimada, 2008, Stroke.

Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Risk factors of atherosclerotic diseases. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerosis cardiovascular diseases for Japanese.

T. Funahashi, K. Shimamoto, H. Daida, 2007, Journal of atherosclerosis and thrombosis.

The elderly.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study.

J. Sasaki, S. Kono, Y. Ikeda, 2013, Journal of atherosclerosis and thrombosis.

Blood pressure lowering effect of low intensity aerobic training in elderly hypertensive patients.

Hiroaki Tanaka, J. Sasaki, K. Arakawa, 1998, Medicine and science in sports and exercise.

Comprehensive risk management for the prevention of cerebro- cardiovascular diseases in Japan

S. Yamashita, H. Iso, H. Shiomi, 2017, Hypertension Research.

Band neutrophil count and the presence and severity of coronary atherosclerosis.

J. Sasaki, S. Kono, K. Arakawa, 1996, American heart journal.

Trial Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic

Itakura, Kortaro Tanaka, Y. Matsuzawa, 2008 .

Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2009, Circulation journal : official journal of the Japanese Circulation Society.

Diabetes mellitus. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

Physical activity in the Japan population: association with blood lipid levels and effects in reducing cardiovascular and all-cause mortality.

Hiroaki Tanaka, J. Sasaki, S. Koba, 2011, Journal of atherosclerosis and thrombosis.

The Risk of Cardiovascular Events in Japanese Hypertensive Patients with Hypercholesterolemia: Sub-Analysis of the Japan Lipid Intervention Trial (J-LIT) Study, a Large-Scale Observational Cohort Study

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2005, Hypertension Research.

Treatment A) lifestyle modification: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT).

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2005, Circulation journal : official journal of the Japanese Circulation Society.

Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Obesity as a risk factor for coronary events in Japanese patients with hypercholesterolemia on low-dose simvastatin therapy.

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2010, Journal of atherosclerosis and thrombosis.

2 Diagnostic Criteria for Dyslipidemia

T. Funahashi, K. Shimamoto, H. Daida, 2007 .

Prevalence of metabolic syndrome in the general Japanese population in 2000.

Y. Ouchi, Y. Matsuzawa, T. Kita, 2006, Journal of atherosclerosis and thrombosis.

THE EFFECTS OF LONG-TERM LOW INTENSITY AEROBIC TRAINING AND THE CESSATION OF TRAINING ON THE SERUM LIPID AND LIPOPROTEIN CONCENTRATIONS IN OLDER PATIENTS

Hiroaki Tanaka, J. Sasaki, A. Kiyonaga, 1994 .

Determination by the SKID Method of Normal Values of Serum Apolipoproteins (A-I, A-II, B, C-II, C-III, and E) in Normolipidemic Healthy Japanese Subjects

J. Sasaki, Y. Akanuma, T. Nakai, 2009 .

Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.

J. Sasaki, K. Arakawa, K. Saku, 1989, Clinical therapeutics.

Treatment B) Drug Therapy

S. Kihara, S. Yamashita, T. Hiro, 2013 .

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease.

J. Sasaki, T. Teramoto, M. Ageta, 2001, Biochimica et biophysica acta.

Natural mutations of apolipoprotein A-I impairing activation of lecithin:cholesterol acyltransferase.

D. Sviridov, Wei Huang, J. Sasaki, 2003, Biochimica et biophysica acta.

Two novel point mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in LCAT deficiency: LCAT (G873 deletion) and LCAT (Gly344-->Ser).

T. Yanase, J. Sasaki, E. Maeda, 1995, Journal of lipid research.

A single amino acid deletion in the carboxy terminal of apolipoprotein A-I impairs lipid binding and cellular interaction.

Wei Huang, J. Sasaki, K. Arakawa, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Statins: beneficial or adverse for glucose metabolism.

J. Sasaki, S. Kono, Mikio Iwashita, 2006, Journal of atherosclerosis and thrombosis.

Effect of soybean crude fiber on the concentrations of serum lipids and apolipoproteins in hyperlipemic subjects.

J. Sasaki, K. Arakawa, M. Funakoshi, 1985, Annals of nutrition & metabolism.

Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial.

Y. Ouchi, S. Yamashita, Y. Ohashi, 2019, Circulation.

A case of nephrotic syndrome with urinary excretion of lipoproteins.

J. Sasaki, K. Arakawa, T. Sata, 1984, Japanese journal of medicine.

A novel homozygous missense mutation in the apo A-I gene with apo A-I deficiency.

J. Sasaki, K. Arakawa, A. Matsunaga, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis.

J. Sasaki, K. Arakawa, K. Saku, 1989, Nephron.

Effects of low-intensity aerobic training on the high-density lipoprotein cholesterol concentration in healthy elderly subjects.

Hiroaki Tanaka, J. Sasaki, M. Shindo, 1999, Metabolism: clinical and experimental.

Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.

J. Sasaki, S. Oikawa, T. Sato, 1999, Kidney international. Supplement.

Apolipoprotein E ε4

S. Sakoda, J. Sasaki, M. Osame, 1994, Neurology.

Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study

S. Yamashita, J. Sasaki, S. Kono, 2017, Journal of atherosclerosis and thrombosis.

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia

J. Sasaki, 2010, Vascular health and risk management.

"Association of apolipoprotein E allele !e4 with late-onset familial and sporadic Alzheimer's disease": Comment.

A. Matsunaga, J. Sasaki, S. Sakoda, 1994 .

Elevated levels of HDL2-cholesterol and apo A-I in national class Japanese male marathon runners.

J. Sasaki, K. Arakawa, K. Saku, 1988, Atherosclerosis.

Effects of enalapril on serum lipoproteins in mild essential hypertension.

J. Sasaki, K. Arakawa, 1989, Clinical therapeutics.

Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

J. Sasaki, H. Sugihara, Mototsugu Nagao, 2023, Scientific Reports.

Response by Kuwabara et al to Letter Regarding Article, "Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial".

Y. Ouchi, J. Sasaki, T. Saikawa, 2020, Circulation.

Characterization of a new human apolipoprotein A-I Yame by direct sequencing of polymerase chain reaction-amplified DNA.

J. Sasaki, K. Arakawa, Y. Teranishi, 1991, Journal of lipid research.

Structural and functional properties of apolipoprotein A-I mutants.

J. Sasaki, A. Matsunaga, T. Koga, 2000, Journal of atherosclerosis and thrombosis.

Characterization of two new human apolipoprotein A-I variants: apolipoprotein A-I Tsushima (Trp-108-->Arg) and A-I Hita (Ala-95-->Asp).

J. Sasaki, K. Arakawa, A. Matsunaga, 1994, Biochimica et biophysica acta.

Kinetics of HDL-apo A-I in the WHHL rabbit, an animal model of familial hypercholesterolemia.

J. Sasaki, K. Arakawa, K. Saku, 1989, Atherosclerosis.

Effects of Hypertension and Type 2 Diabetes Mellitus on the Risk of Total Cardiovascular Events in Japanese Patients with Hypercholesterolemia: Implications from the Japan Lipid Intervention Trial (J-LIT)

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2007, Hypertension Research.

Alterations in lipoprotein with discontinuation of probucol

J. Sasaki, K. Arakawa, K. Saku, 1987 .

Absolute risk of cardiovascular disease and lipid management targets.

S. Kihara, S. Yamashita, T. Hiro, 2013, Journal of atherosclerosis and thrombosis.

Effect of captopril on high-density lipoprotein subfractions in patients with mild to moderate essential hypertension.

J. Sasaki, K. Arakawa, 1989, Clinical therapeutics.

Comparative effects of monatepil, a novel calcium antagonist with alpha 1-adrenergic-blocking activity, and nitrendipine on lipoprotein and carbohydrate metabolism in patients with hypertension.

T. Ogihara, J. Sasaki, K. Arakawa, 1994, American journal of hypertension.

Relation of C4b-binding protein to athero-sclerosis of the descending thoracic aorta.

J. Sasaki, K. Arakawa, M. Kusuda, 1996, Artery.

Comment on the 2013 ACC/AHA guidelines on Lifestyle Management to Reduce Cardiovascular Risk by the JAS Guidelines Committee.

J. Sasaki, S. Koba, C. Maruyama, 2014, Journal of atherosclerosis and thrombosis.

Comment on the new guidelines in USA by the JAS guidelines committee.

J. Sasaki, H. Arai, T. Teramoto, 2014, Journal of atherosclerosis and thrombosis.

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

Y. Matsuzawa, K. Shimada, M. Matsuzaki, 2009, Atherosclerosis.

Chronic kidney disease.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.

A long-term aerobic exercise program decreases the obesity index and increases the high density lipoprotein cholesterol concentration in obese children.

J. Sasaki, K. Arakawa, H. Tanaka, 1987, International journal of obesity.

Vascular Health and Risk Management Dovepress Pitavastatin Approved for Treatment of Primary Hypercholesterolemia and Combined Dyslipidemia

J. Sasaki, 2022 .

Vascular Health and Risk Management Dovepress Pitavastatin Approved for Treatment of Primary Hypercholesterolemia and Combined Dyslipidemia

J. Sasaki, 2022 .

Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT).

Y. Matsuzawa, K. Shimamoto, M. Matsuzaki, 2007, Atherosclerosis.

Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.

J. Sasaki, K. Arakawa, K. Saku, 1989, Clinical therapeutics.

The elderly.

S. Kihara, S. Yamashita, T. Hiro, 2014, Journal of atherosclerosis and thrombosis.